Stocks Trading Up: ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)

Posted by Ryan Mandell May 24, 2013 0 Comment 1826 views


Northern, WI 05/24/2013 (GDPInsider) – ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is up 43.07% in early morning trading after starting the day at 2.10, 0.08 cents above its previous close of 2.02. The range so far is 2.08 and 2.70 and the stock is trading on very strong volume of 4.838 million – more than double average volume of 2.063 million.

The biopharmaceutical company recently announced that its CEO, Jonathan Lewis, M.D., Ph.D., is slated to present at the 38th Annual Deutsche Bank Health Care Conference on Wednesday, May 29th, 2013. Lewis will present at 8:00 a.m. ET at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

The increase activity has pushed ZIOP over into overbought territory and the stock now has a RSI of 72.54. At present market valuation ZIOP is up 33.91% on its SMA20 and 0.94 on its SMA50. ZIOP’s technical chart shows a marginal uptrend from the relatively flat trading which existed since the start of May 2013. Analysts have set a target price of 2.88 for the stock.

Is ZIOP a solid investment at these levels? Get exclusive data and trends here.

Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE) opened trading today at 3.35, a solid 0.33 cents above previous close of 3.03. Market activity has seen volume shoot past average of 3.516 million, sitting currently at 4.668 million shares. The strong trading activity has pushed YGE up 9.24% on a range of 3.28 and 3.54.

YGE is an energy company focusing on the production of photovoltaic (PV) modules. Recent announcements include news that YGE Singapore is set to supply Yingli 10.269 MW of multicrystalline PV modules to Amcorp Power, a subsidiary of Amcorp Group Berhad based in Malayasia. The deal is expected to yield revenues as the project entails the utilization of 41,076 pieces of YGE 60 Cell Series multicrystalline module with peak power of 250 watt.

YGE has traded positively in the last week or so and is now 30% above its SMA20 and 46.52% above its SMA50. The stock still has a relatively healthy RSI of 66.52, although at these levels it is close to being overbought.

How Should Investors Trade YGE Now? Get exclusive insights and updates here.

 

 

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.

 

 


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment